Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Natixis Advisors L.P.

Natixis Advisors L.P. raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.3% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 333,098 shares of the medical research company’s stock after buying an additional 4,214 shares during the quarter. Natixis Advisors L.P.’s holdings in Thermo Fisher Scientific were worth $176,805,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Accurate Wealth Management LLC boosted its position in shares of Thermo Fisher Scientific by 6.3% in the 3rd quarter. Accurate Wealth Management LLC now owns 553 shares of the medical research company’s stock worth $268,000 after buying an additional 33 shares in the last quarter. Kingswood Wealth Advisors LLC grew its position in shares of Thermo Fisher Scientific by 14.2% in the third quarter. Kingswood Wealth Advisors LLC now owns 995 shares of the medical research company’s stock valued at $504,000 after purchasing an additional 124 shares during the last quarter. Tectonic Advisors LLC raised its position in shares of Thermo Fisher Scientific by 18.7% during the 3rd quarter. Tectonic Advisors LLC now owns 2,245 shares of the medical research company’s stock worth $1,136,000 after purchasing an additional 353 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its holdings in Thermo Fisher Scientific by 1.2% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 82,690 shares of the medical research company’s stock valued at $41,855,000 after buying an additional 997 shares during the last quarter. Finally, Stratos Wealth Advisors LLC increased its position in Thermo Fisher Scientific by 46.8% during the third quarter. Stratos Wealth Advisors LLC now owns 4,195 shares of the medical research company’s stock worth $2,124,000 after buying an additional 1,338 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on TMO shares. The Goldman Sachs Group upped their target price on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. JPMorgan Chase & Co. boosted their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a report on Thursday, April 25th. Royal Bank of Canada raised their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Barclays increased their target price on Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 25th. Finally, Evercore ISI upped their price objective on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $607.35.

Thermo Fisher Scientific Stock Down 0.5 %

Shares of NYSE TMO traded down $3.10 on Thursday, hitting $571.89. The company had a trading volume of 551,490 shares, compared to its average volume of 1,537,610. The firm has a market capitalization of $218.30 billion, a P/E ratio of 36.69, a PEG ratio of 2.36 and a beta of 0.80. The company has a quick ratio of 1.33, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82. The business has a 50 day moving average of $575.03 and a two-hundred day moving average of $531.97.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating the consensus estimate of $4.70 by $0.41. The business had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.64 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were paid a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is 10.01%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the sale, the chief executive officer now owns 123,816 shares in the company, valued at $70,873,516.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total value of $5,724,100.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $70,873,516.56. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Debora L. Spar sold 164 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the sale, the director now owns 1,207 shares in the company, valued at approximately $660,192.79. The disclosure for this sale can be found here. In the last 90 days, insiders sold 62,277 shares of company stock valued at $35,373,364. Insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.